FDA News: Approvals, Adcomms, Complete Response Letters and Guidances

One red lottery winner or rare disease, multi-level personification, power, reverse search, secret sample, special spy, close-up. Company leader

Rare diseases

Through flux and fluidity, FDA keeps coming back to rare disease

Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.

July 8, 2026

6 min read

Heather McKenzie

Manufacturing

Amgen recalls almost 1 million bottles of heart failure drug over quality issue

July 8, 2026

1 min read

Nick Paul Taylor

Podcast

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

July 8, 2026

1 min read

Jef Akst

Approvals

Vera moves into growing kidney disease space with FDA’s accelerated IgAN nod

July 7, 2026

2 min read

Annalee Armstrong

Opinion

The FDA must put biotech at its center or continue to cede early research to China

July 6, 2026

4 min read

Kendalle Burlin O’Connell

FDA

Despite chaos and churn, FDA decisions hold mostly steady in H1 2026

July 6, 2026

8 min read

Tristan Manalac

Editorial

Biotech’s China problem: An issue of national security or economic value for the US?

July 2, 2026

6 min read

Jef Akst

FEATURED STORIES

3D. rocket soaring. Different rockets fly high and stand out. different from others, concept startup idea, new generation, faster work better

Huntington’s disease

Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill

A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.

June 30, 2026

4 min read

Heather McKenzie

Business meeting concept as a group united together as a partnership symbol of strength.

Duchenne muscular dystrophy

Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy

The FDA plans to hold an advisory committee meeting to discuss Capricor Therapeutics’ application for deramiocel, which the agency rejected last July. The news surprised CEO Linda Marbán, who told BioSpace the FDA has not communicated any issues of concern with the company’s resubmitted application.

June 26, 2026

4 min read

Heather McKenzie

Solution problem concept. Man walking on tightrope. Life coaching, transformation idea. Brainstorming in business. Vector illustration

Opinion

The hidden cost of FDA unpredictability

When the variance can’t be modeled, even disciplined biotech investors stop deploying. Here’s the cheapest fix for biotech’s investability problem.

June 26, 2026

6 min read

David Crean

Subscribe to ClinicaSpace

Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday

THE LATEST

FDA

FDA Gives Thumbs-Up to Sunovion’s Under-the-Tongue Parkinson’s Drug Kynmobi

“Today’s approval of Kynmobi advances treatment options for people with Parkinson’s disease who experience OFF episodes and the associated disruption of everyday activities,” said Antony Loebel, Sunovion’s president and chief executive officer.

May 22, 2020

3 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: May 22

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.

May 22, 2020

4 min read

BioSpace Editorial Staff

Policy

Biopharma Update on the Novel Coronavirus: May 21

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.

May 21, 2020

4 min read

BioSpace Editorial Staff

Policy

Biopharma Update on the Novel Coronavirus: May 20

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.

May 20, 2020

6 min read

BioSpace Editorial Staff

FDA

Lynparza Becomes Second PARP Inhibitor Approved for Prostate Cancer, Just Days Behind the First

Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.

May 20, 2020

3 min read

Alex Keown